Individuals living with type 2 diabetes can manage their condition better by using once-weekly insulin icodec rather than insulin degludec, a new study has claimed.
Latest data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2022 has reported that nearly 40 per cent of people living with type 2 diabetes who use once-weekly insulin icodec had an HbA1c <7.0 per cent.
Whereas only 26 per cent of adults living with the condition who are treated with insulin degludec had an HbA1c <7.0 per cent, the study has revealed.
However, insulin icodec is currently not permitted for use in the United Kingdom (UK) as it is only an investigational medicine.
Principal investigator of ONWARDS 2, Dr Athena Philis-Tsimikas said: “Once-weekly insulin would be a remarkable step forward in insulin innovation.
“It could offer people with type 2 diabetes reduced treatment complexity and burden by reducing the number of basal insulin injections from 365 to 52 per year, without compromising management of blood sugar.”
People with diabetes in ONWARDS 2 reported significantly greater satisfaction in favour of once-weekly insulin icodec compared with insulin degludec at 26 weeks as assessed by the Diabetes Treatment Satisfaction Questionnaire (DTSQ).
The mean weekly insulin dose was 268 U/week for insulin icodec vs 244 U/week for insulin degludec.
No severe hypoglycaemia events were observed for people treated with insulin icodec.